Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3
Eiger BioPharmaceuticals (Nasdaq: EIGR) announced a conference call on November 3, 2022, at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eiger BioPharmaceuticals (Nasdaq: EIGR) announced a conference call on November 3, 2022, at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update. The company is focused on developing innovative therapies for hepatitis delta virus (HDV) and other serious diseases, with two first-in-class therapies in Phase 3 that target viral replication. All five rare disease programs have received FDA breakthrough therapy designation.
Positive
- Eiger's HDV platform includes two first-in-class therapies in Phase 3.
- All five rare disease programs have received FDA breakthrough therapy designation.
Negative
- None.
Details
News Market Reaction – EIGR
The recorded move for EIGR in the trading session of this news was +1.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Live Conference Call and Webcast at 4:30 PM ET -
PALO ALTO, Calif., Oct. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update.
The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, please register in advance at https://register.vevent.com/register/BI87b8efa326b64c63bd59eabef4f465ab to receive the dial-in number and unique passcode to access the call. The webcast will be archived and available for replay for at least 90 days after the event.
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-third-quarter-2022-financial-results-and-business-update-on-thursday-november-3-301657595.html
SOURCE Eiger BioPharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.